NextCure (NASDAQ:NXTC) Shares Up 1.2% – What’s Next?

NextCure, Inc. (NASDAQ:NXTC) shot up 1.2% on Tuesday . The company traded as high as $6.13 and last traded at $6.07. 3,656 shares changed hands during mid-day trading, a decline of 62% from the average session volume of 9,628 shares. The stock had previously closed at $6.00.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on NXTC. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of NextCure in a research report on Tuesday, July 1st. Piper Sandler set a $15.00 price target on shares of NextCure and gave the stock an “overweight” rating in a research note on Tuesday, July 15th. Weiss Ratings restated a “sell (e+)” rating on shares of NextCure in a research note on Saturday, September 27th. Finally, LADENBURG THALM/SH SH upgraded NextCure to a “hold” rating in a research note on Tuesday, July 8th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $25.50.

NextCure Price Performance

The firm’s 50-day moving average price is $5.30 and its 200 day moving average price is $5.34. The firm has a market cap of $16.27 million, a P/E ratio of -0.24 and a beta of 1.34.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($11.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.62) by ($6.67). Analysts forecast that NextCure, Inc. will post -1.87 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NXTC. Citadel Advisors LLC lifted its position in shares of NextCure by 40.6% in the 4th quarter. Citadel Advisors LLC now owns 78,678 shares of the company’s stock worth $61,000 after buying an additional 22,724 shares during the last quarter. Cable Car Capital LP raised its stake in NextCure by 13.1% during the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after acquiring an additional 88,040 shares during the period. Finally, Pfizer Inc raised its stake in NextCure by 29.7% during the first quarter. Pfizer Inc now owns 1,891,763 shares of the company’s stock worth $909,000 after acquiring an additional 433,213 shares during the period. 42.65% of the stock is currently owned by institutional investors.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.